Pharmacokinetic Properties of Fused Hirudin and RSA
. | HLAH6 . | RSA . |
---|---|---|
jT | .151 ± .009 | .125 ± .002 |
j3 | .792 ± .019 | .314 ± .001 |
j3.5 | .436 ± .055 | .248 ± .018 |
Ap | .191 ± .008 | .399 ± .007 |
Aw | .160 ± .053 | .109 ± .035 |
Ae | .649 ± .061 | .532 ± .024 |
. | HLAH6 . | RSA . |
---|---|---|
jT | .151 ± .009 | .125 ± .002 |
j3 | .792 ± .019 | .314 ± .001 |
j3.5 | .436 ± .055 | .248 ± .018 |
Ap | .191 ± .008 | .399 ± .007 |
Aw | .160 ± .053 | .109 ± .035 |
Ae | .649 ± .061 | .532 ± .024 |
Comparison of fractional catabolic rates and compartmental distributions of HLA(H)6 (this study, see Fig 8) and of RSA.36 Symbols: jT , j3 , and j3.5 , fractions of fusion protein or RSA in total body, plasma compartment, and plasma compartment plus noncirculating vessel wall catabolized per day; Ap , Aw , and Ae , fractions of total body fusion protein or RSA in plasma, noncirculating vessel wall, and extravascular compartments, respectively. Data were calculated from individual plasma curves as described in Materials and Methods.